These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 20075048)

  • 1. Effectiveness of the pneumococcal polysaccharide vaccine in preventing pneumonia in the elderly.
    Domínguez A; Izquierdo C; Salleras L; Ruiz L; Sousa D; Bayas JM; Nebot M; Varona W; Celorrio JM; Carratalà J;
    Eur Respir J; 2010 Sep; 36(3):608-14. PubMed ID: 20075048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study.
    Vila-Corcoles A; Salsench E; Rodriguez-Blanco T; Ochoa-Gondar O; de Diego C; Valdivieso A; Hospital I; Gomez-Bertomeu F; Raga X
    Vaccine; 2009 Mar; 27(10):1504-10. PubMed ID: 19171174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study.
    Vila-Córcoles A; Ochoa-Gondar O; Hospital I; Ansa X; Vilanova A; Rodríguez T; Llor C;
    Clin Infect Dis; 2006 Oct; 43(7):860-8. PubMed ID: 16941367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in patients with chronic pulmonary diseases: a matched case-control study.
    Vila-Corcoles A; Ochoa-Gondar O; Rodriguez-Blanco T; Gutierrez-Perez A; Vila-Rovira A;
    Hum Vaccin Immunother; 2012 May; 8(5):639-44. PubMed ID: 22634442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects.
    Vila-Córcoles A; Ochoa-Gondar O; Llor C; Hospital I; Rodríguez T; Gómez A
    Eur Respir J; 2005 Dec; 26(6):1086-91. PubMed ID: 16319340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older.
    Vila-Corcoles A; Ochoa-Gondar O; Guzmán JA; Rodriguez-Blanco T; Salsench E; Fuentes CM;
    BMC Infect Dis; 2010 Mar; 10():73. PubMed ID: 20298596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of pneumococcal vaccination for elderly people in Catalonia, Spain: a case-control study.
    Dominguez A; Salleras L; Fedson DS; Izquierdo C; Ruiz L; Ciruela P; Fenoll A; Casal J
    Clin Infect Dis; 2005 May; 40(9):1250-7. PubMed ID: 15825026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of 23-valent pneumococcal polysaccharide vaccine and seasonal influenza vaccine for pneumonia among the elderly - Selection of controls in a case-control study.
    Kondo K; Suzuki K; Washio M; Ohfuji S; Fukushima W; Maeda A; Hirota Y;
    Vaccine; 2017 Aug; 35(36):4806-4810. PubMed ID: 28818473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan.
    Kawakami K; Ohkusa Y; Kuroki R; Tanaka T; Koyama K; Harada Y; Iwanaga K; Yamaryo T; Oishi K
    Vaccine; 2010 Oct; 28(43):7063-9. PubMed ID: 20723631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effectiveness of the polysaccharide pneumococcal vaccine for the prevention of hospitalizations due to Streptococcus pneumoniae community-acquired pneumonia in the elderly differs between the sexes: results from the Community-Acquired Pneumonia Organization (CAPO) international cohort study.
    Wiemken TL; Carrico RM; Klein SL; Jonsson CB; Peyrani P; Kelley RR; Aliberti S; Blasi F; Fernandez-Gonzalez R; Lopardo G; Ramirez JA;
    Vaccine; 2014 Apr; 32(19):2198-203. PubMed ID: 24613522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of 7-valent pneumococcal conjugate vaccine in the prevention of invasive pneumococcal disease in children aged 7-59 months. A matched case-control study.
    Domínguez A; Ciruela P; García-García JJ; Moraga F; de Sevilla MF; Selva L; Coll F; Muñoz-Almagro C; Planes AM; Codina G; Jordán I; Esteva C; Hernández S; Soldevila N; Cardeñosa N; Batalla J; Salleras L
    Vaccine; 2011 Nov; 29(48):9020-5. PubMed ID: 21939724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the pneumococcal vaccine on long-term morbidity and mortality of adults at high risk for pneumonia.
    Johnstone J; Eurich DT; Minhas JK; Marrie TJ; Majumdar SR
    Clin Infect Dis; 2010 Jul; 51(1):15-22. PubMed ID: 20504233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive disease and hospital-treated pneumonia among people aged ≥65 years: a retrospective case-control study.
    Leventer-Roberts M; Feldman BS; Brufman I; Cohen-Stavi CJ; Hoshen M; Balicer RD
    Clin Infect Dis; 2015 May; 60(10):1472-80. PubMed ID: 25669354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥ 60 years: 3 years of follow-up in the CAPAMIS study.
    Ochoa-Gondar O; Vila-Corcoles A; Rodriguez-Blanco T; Gomez-Bertomeu F; Figuerola-Massana E; Raga-Luria X; Hospital-Guardiola I
    Clin Infect Dis; 2014 Apr; 58(7):909-17. PubMed ID: 24532544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of pneumococcal vaccination in hospitalized adults with community-acquired pneumonia.
    Johnstone J; Marrie TJ; Eurich DT; Majumdar SR
    Arch Intern Med; 2007 Oct; 167(18):1938-43. PubMed ID: 17923592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 23-valent pneumococcal polysaccharide vaccine is effective in elderly adults over 75 years old--Taiwan's PPV vaccination program.
    Tsai YH; Hsieh MJ; Chang CJ; Wen YW; Hu HC; Chao YN; Huang YC; Yang CT; Huang CC
    Vaccine; 2015 Jun; 33(25):2897-902. PubMed ID: 25936662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of pneumococcal polysaccharide vaccine in older adults.
    Jackson LA; Neuzil KM; Yu O; Benson P; Barlow WE; Adams AL; Hanson CA; Mahoney LD; Shay DK; Thompson WW;
    N Engl J Med; 2003 May; 348(18):1747-55. PubMed ID: 12724480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of 23-valent pneumococcal polysaccharide vaccination in preventing community-acquired pneumonia hospitalization and severe outcomes in the elderly in Spain.
    Domínguez À; Soldevila N; Toledo D; Torner N; Force L; Pérez MJ; Martín V; Rodríguez-Rojas L; Astray J; Egurrola M; Sanz F; Castilla J;
    PLoS One; 2017; 12(2):e0171943. PubMed ID: 28187206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Community-acquired pneumonia requiring hospitalisation. Factors of importance for the short-and long term prognosis.
    Hedlund J
    Scand J Infect Dis Suppl; 1995; 97():1-60. PubMed ID: 8584866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of polysaccharide pneumococcal vaccine in HIV-infected patients: a case-control study.
    Peñaranda M; Falco V; Payeras A; Jordano Q; Curran A; Pareja A; Samperiz G; Dalmau D; Ribera E; Riera M
    Clin Infect Dis; 2007 Oct; 45(7):e82-7. PubMed ID: 17806042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.